|
Item 5.02
.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
(e) Compensatory Arrangements with Certain Officers.
The Board of Directors (the “Board”) of Progenics Pharmaceuticals, Inc. (the “Company”) previously adopted the Progenics Pharmaceuticals, Inc. 2018 Performance Incentive Plan (the “2018 Plan”), subject to stockholder approval of the 2018 Plan. As disclosed in Item 5.07 of this Form 8-K, the Company’s stockholders have approved the 2018 Plan.
The following summary of the 2018 Plan is qualified in its entirety by reference to the text of the 2018 Plan, which is filed as Exhibit 10.1 hereto and incorporated herein by reference.
The Board or one or more committees appointed by the Board will administer the 2018 Plan. The Board has delegated general administrative authority for the 2018 Plan to the Compensation Committee of the Board. The administrator of the 2018 Plan has broad authority under the 2018 Plan to, among other things, select participants and determine the types of awards that they are to receive, and determine the number of shares that are to be subject to awards and the terms and conditions of awards, including the price (if any) to be paid for the shares or the award.
Persons eligible to receive awards under the 2018 Plan include directors of the Company, officers or employees of the Company or any of its subsidiaries, and certain consultants and advisors to the Company or any of its subsidiaries.
The maximum number of shares of the Company’s common stock (the “Common Stock”) that may be issued or transferred pursuant to awards under the 2018 Plan equals: (1) 4,800,000 shares, plus (2) 2,523,895 shares (which represents the number of shares that were available for additional award grant purposes under the Progenics Pharmaceuticals, Inc. 2005 Stock Incentive Plan (the “2005 Plan”) immediately prior to the termination of the authority to grant new awards under the 2005 Plan as of June 13, 2018, the date of stockholder approval of the 2018 Plan), plus (3) the number of any shares subject to stock options granted under the 2005 Plan and outstanding as of June 13, 2018 which expire, or for any reason are cancelled or terminated, after that date without being exercised, plus (4) the number of any shares subject to restricted stock and restricted stock unit awards granted under the 2005 Plan that are outstanding and unvested as of June 13, 2018 which are forfeited, terminated, cancelled, or otherwise reacquired after that date without having become vested (with such any shares taken into account based on the premium share-counting rule discussed below for full-value awards).
Shares issued in respect of any “full-value award” granted under the 2018 Plan will be counted against the share limit described in the preceding paragraph as 1.42 shares for each share actually issued in connection with the award. For example, if the Company granted 100 shares of Common Stock under the 2018 Plan, 142 shares would be charged against the share limit with respect to that award. For this purpose, a “full-value award” means any award granted under the plan other than a stock option or stock appreciation right.
Except as described in the next sentence, shares that are subject to or underlie awards granted under the 2018 Plan which expire or for any reason are cancelled or terminated, are forfeited, fail to vest, or for any other reason are not paid or delivered under the 2018 Plan will not be counted against the plan’s share limit and will be available for subsequent awards under the 2018 Plan. Shares that are exchanged by a participant or withheld by the Company as full or partial payment in connection with any award under the 2018 Plan, as well as any shares exchanged by a participant or withheld by the Company or one of its subsidiaries to satisfy the tax withholding obligations related to any award, will be counted against the plan’s share limit and will not be available for subsequent awards under the 2018 Plan. To the extent that an award granted under the 2018 Plan is settled in cash or a form other than shares, the shares that would have been delivered had there been no such cash or other settlement will not be counted against the plan’s share limit and will be available for subsequent awards under the 2018 Plan. In the event that shares are delivered in respect of a dividend equivalent right granted under the 2018 Plan, the number of shares delivered with respect to the award will be counted against the plan’s share limit. To the extent that shares are delivered pursuant to the exercise of a stock appreciation right or stock option granted under the 2018 Plan, the number of underlying shares as to which the exercise related will be counted against the plan’s share limit, as opposed to only counting the shares issued.
The types of awards that may be granted under the 2018 Plan include stock options, stock appreciation rights, restricted stock, stock units, stock bonuses and other forms of awards granted or denominated in Common Stock or units of Common Stock, as well as certain cash bonus awards.
As is customary in incentive plans of this nature, each share limit and the number and kind of shares available under the 2018 Plan and any outstanding awards, as well as the exercise or purchase prices of awards, and performance targets under certain types of performance-based awards, are subject to adjustment in the event of certain reorganizations, mergers, combinations, recapitalizations, stock splits, stock dividends, or other similar events that change the number or kind of shares outstanding, and extraordinary dividends or distributions of property to the stockholders.